Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs.
Click here to view the Ocugen 2022 R&D Day event
February 1, 2023 Ocugen Appoints Quan A. Vu as Chief Business Officer
January 31, 2023 Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference